TNGX
NASDAQ HealthcareTango Therapeutics, Inc. - Common Stock
Biotechnology
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $21.50 |
|---|---|
| 成交量 | 2,956,288 |
| 市值 | 3.11B |
| 贝塔系数 | 1.220 |
| RSI（14日） | 43.6 |
| 200日均线 | $13.05 |
| 50日均线 | $22.38 |
| 52周最高 | $28.41 |
| 52周最低 | $2.45 |
| Forward P/E | -13.52 |
| Price / Book | 8.44 |
🎯 投资策略评分
TNGX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (77/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🔪 Falling Knife (19/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TNGX in your text
粘贴任何文章、记录或帖子 — 工具将提取 TNGX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.